Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    NIAID | Open Studies | Exclude Unknown | anthrax OR botulism OR plague OR pox OR tularemia OR Viral hemorrhagic fever OR Junin OR Machupo OR Guanarito OR Lassa OR Hanta OR Rift Valley OR Dengue OR Ebola OR Marburg
Show Display Options
RSS Create an RSS feed from your search for:
NIAID | Open Studies | Exclude Unknown | anthrax OR botulism OR plague OR pox OR tularemia OR Viral hemorrhagic fever OR Junin OR Machupo OR Guanarito OR Lassa OR Hanta OR Rift Valley OR Dengue OR Ebola OR Marburg
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
2 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
3 Recruiting GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Condition: Persistent Ebola Virus
Interventions: Drug: GS-5734;   Other: Placebo Comparator
4 Recruiting Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Condition: Anthrax
Intervention:
5 Recruiting The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Conditions: Zika Virus Disease (Disorder);   Dengue;   Chikungunya
Intervention:
6 Not yet recruiting Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure
Condition: Healthy Volunteers
Intervention: Drug: rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)
7 Not yet recruiting MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
Conditions: Marburg Disease;   Ebola Disease
Interventions: Biological: MVA Multi-Filo Ebola Vaccine;   Biological: Ad26 Zaire Ebola Vaccine
8 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
9 Recruiting Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: rDEN3∆30;   Biological: Placebo
10 Not yet recruiting Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Condition: Dengue
Interventions: Biological: TV005 vaccine;   Biological: Placebo
11 Not yet recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
12 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
13 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
14 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
15 Recruiting Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
Condition: Botulism
Interventions: Biological: NTM-1632;   Other: Placebo
16 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
17 Recruiting Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers
Condition: Healthy
Intervention: Drug: ZMAPP
18 Recruiting Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
Condition: Viral Infection
Interventions: Drug: UV-4B 30 mg oral solution;   Drug: UV-4B 75 mg oral solution;   Drug: UV-4B 150 mg oral solution;   Drug: UV-4B X mg (dose to be determined) oral solution;   Drug: UV-4B Y mg (dose to be determined) oral solution;   Drug: Placebo
19 Recruiting A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
Condition: Yellow Fever
Interventions: Biological: MVA Smallpox Vaccine;   Biological: YF Vax 17D Strain;   Drug: ISA-720;   Biological: MVA-BN Yellow Fever Vaccine;   Other: Placebo

Indicates status has not been verified in more than two years